Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Stro source : Www.sutrobio.com save search
2023 American Society of Clinical Oncology (ASCO) Annual Meeting – Presentation
Published: 2023-06-03 (Crawled : 00:20) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
| Email alert
Add to watchlist
presentation meeting
Sutro Biopharma to Participate in the Jefferies Healthcare Conference
Published: 2023-05-31 (Crawled : 12:01) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 0.22%
H: 4.55%
C: -2.81%
conference biopharma
2023 American Society of Pediatric Hematology / Oncology (ASPHO) Annual Meeting – Poster
Published: 2023-05-17 (Crawled : 22:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: -1.04%
H: 0.18%
C: -7.03%
meeting
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
Published: 2023-05-08 (Crawled : 12:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: -0.18%
H: 2.56%
C: 0.37%
conference life biopharma sciences
Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
Published: 2023-04-27 (Crawled : 21:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: -0.69%
H: 1.16%
C: -1.39%
biopharma research
2023 American Association for Cancer Research Annual Meeting (AACR) – Poster
Published: 2023-04-18 (Crawled : 18:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 0.21%
H: 0.43%
C: -3.84%
association cancer research meeting
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
Published: 2023-03-30 (Crawled : 21:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: -0.89%
H: 6.31%
C: 4.05%
business year biopharma financial
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-03-17 (Crawled : 20:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
| Email alert
Add to watchlist
nasdaq biopharma grants
13th Annual World ADC London 2023 – Presentation
Published: 2023-03-14 (Crawled : 16:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 1.1%
H: 8.01%
C: 0.36%
presentation
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
Published: 2023-03-01 (Crawled : 13:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 1.6%
H: 3.4%
C: 0.7%
biopharma care conference health
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
Published: 2023-02-28 (Crawled : 13:00) - sutrobio.com
ABT | News | $105.9 -1.57% 1.3M
|
Health Technology
|
| O: 0.07%
H: 2.58%
C: 1.88%
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 0.0%
H: 5.06%
C: -1.57%
biopharma medical
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-02-17 (Crawled : 21:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
| Email alert
Add to watchlist
biopharma nasdaq grants
BioNova Announces First Patient Dosed in a Phase 1/2 Study of BN301 for the Treatment of Hematologic Malignancies in China
Published: 2023-02-13 (Crawled : 17:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: -0.31%
H: 8.62%
C: -1.88%
bn301 treatment china study phase 1
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers – Molecular Cancer Therapeutics – AACR Journals
Published: 2023-02-07 (Crawled : 00:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -3.99%
stro-002 treatment therapeutics molecular cancer aacr journals
41st Annual JP Morgan Healthcare Conference – Presentation
Published: 2023-01-12 (Crawled : 19:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 5.08%
H: 4.22%
C: -2.36%
conference presentation
Update on STRO-002 Program and Plans for Registrational Trial in Advanced Ovarian Cancer – Presentation
Published: 2023-01-09 (Crawled : 23:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 1.93%
H: 0.89%
C: -14.08%
stro-002 program trial presentation update cancer ovarian cancer
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Published: 2023-01-09 (Crawled : 22:00) - sutrobio.com
PCVX | $60.31 -0.94% 180K
|
Health Technology
|
| O: -0.3%
H: 1.79%
C: 0.35%
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 1.93%
H: 0.89%
C: -14.08%
stro-002 biopharma update cancer study ovarian cancer phase 1
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-04 (Crawled : 13:00) - sutrobio.com
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 1.37%
H: 4.31%
C: -0.37%
biopharma conference
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
Published: 2022-12-21 (Crawled : 13:00) - sutrobio.com
PCVX | $60.31 -0.94% 180K
|
Health Technology
|
| O: 0.22%
H: 3.45%
C: 3.2%
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 4.79%
H: 1.43%
C: 0.0%
stro-002 biopharma update cancer ovarian cancer
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Published: 2022-12-20 (Crawled : 22:00) - sutrobio.com
PPRUF | News | $340.0 1.5K
|
Consumer Non-Durables
|
| O: 2.83%
H: 2.66%
C: -0.36%
PPRUY | News | $33.79 360K
|
Manufacturing
|
| O: 1.46%
H: 1.58%
C: 0.82%
PCVX | $60.31 -0.94% 180K
|
Health Technology
|
| O: 0.22%
H: 3.45%
C: 3.2%
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 4.79%
H: 1.43%
C: 0.0%
biopharma grant agreement
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
LICN | $0.7885 40.8% 11M
|
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.